TEVA
failedTeva Pharmaceutical Industries Limited
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Teva's 6.3% gap up on 3x volume signals Wall Street is increasingly convinced that the company's multi-year turnaround under CEO Richard Francis is reaching an inflection point. The 'Pivot to Growth' strategy is delivering tangible results — Austedo's continued strength as a best-in-class treatment for tardive dyskinesia and Huntington's chorea is driving outsized revenue growth, while the recent launch of their Stelara biosimilar (Selarsdi) opens a meaningful new revenue stream in the lucrative biosimilar space. Investors are likely encouraged by the combination of durable generic drug cash flows, a growing innovative pipeline, and visible de-leveraging that collectively compress the equity risk premium that has weighed on Teva for years. The volume surge suggests this is not just a short-covering rally but genuine institutional repositioning. Teva has labored under opioid litigation overhang, massive debt from the Actavis acquisition, and years of execution missteps — all of which created a deeply discounted valuation. With each quarter of clean execution, raised guidance, and debt reduction, the bear case erodes further. The market appears to be pricing in a scenario where Teva sustains mid-to-high single-digit revenue growth, expands margins, and approaches investment-grade leverage ratios within 12-18 months, supporting a meaningful multiple re-rating from historically depressed levels.
Analyzed by rerate-v2+glm-5.2 · Jul 30, 2026
Catalysts
- Austedo revenue acceleration and potential best-in-class positioning driving peak sales estimates higher
- Stelara biosimilar launch capturing meaningful market share in a multi-billion-dollar franchise
- Continued debt reduction improving balance sheet quality and reducing interest expense drag
- Raised FY guidance reflecting management confidence and operational momentum
- Pipeline advances including TEV-748 and other neuroscience assets creating optionality
- Potential resolution or further clarity on remaining opioid litigation overhang
Risks
- Generic drug pricing pressure could erode the base business that funds the pivot
- Austedo faces eventual biosimilar/generic competition that could plateau growth
- Biosimilar market is increasingly crowded, limiting share capture for Stelara copy
- Remaining opioid litigation and settlement payments could pressure FCF
- High leverage still leaves balance sheet vulnerable to interest rate environment
- Revenue concentration risk if Austedo growth disappoints
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| 📍 Day 1 | $35.01 | $35.66 | $34.56 | 4.70M |
| Day 2 | $34.46 | $35.07 | $33.78 | 6.21M |
| Day 3 | $34.43 | $34.65 | $34.05 | 4.92M |
| Day 4 | $34.72 | $34.98 | $33.89 | 4.96M |
| Day 5 | $34.81 | $34.92 | $34.38 | 4.13M |
Signal Breakdown
Gap held — only 9% erased, price maintained gains
Volume sustained — only 12% decline suggests continued accumulation
Lower highs with peak close on day 1 — price action suggests distribution, not accumulation
Moderate drawdown (2.7%)
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026